August 23, 2017

Nordic Nanovector ASA – Results for Second Quarter and First Half Year 2017

All operations on track, strong data presented at ICML confirm Betalutin®’s promising efficacy and safety profile in recurrent iNHL patients, pivotal Phase 2 study, PARADIGME to...
Read more
August 21, 2017

Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial

60 volunteers to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage im...
Read more
August 17, 2017

Altimmune Announces $14.7 Million Series B Preferred Stock Offering

GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive sec...
Read more
August 17, 2017

MIPS: INTERIM REPORT JANUARY – JUNE 2017

APRIL – JUNE Net sales increased by 55% to MSEK 36.6 (23.6) Operating profit rose to MSEK 11.0 (5.6). Adjusted operating profit* increased to MSEK 11.5 (7.4) Operating...
Read more
August 17, 2017

BONESUPPORT – Q2 2017 Interim Report – invitation to conference call and webcast

Lund, Sweden, 08.00 CEST, 17 August 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trau...
Read more
August 16, 2017

NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2017 (UNAUDITED)

Company Highlights, January – June 2017 Patient enrolment for Nexstim’s supplementary Phase III Trial in Stroke Rehabilitation (E-FIT) using its NBT® system is progressi...
Read more
August 15, 2017

NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 22 NOVEMBER 2017

Oslo, Norway, 14 August 2017 Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for ...
Read more
August 14, 2017

Invitation to second quarter and first half 2017 results presentation Thursday 24 August

Oslo, Norway, 14 August 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its second q...
Read more
August 11, 2017

Notice of Nexstim Plc’s Half-Yearly Report H1 2017

11 August 2017 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimula...
Read more
August 10, 2017

Strongbridge Biopharma plc to Present at the Canaccord Genuity 37th Annual Growth Conference

DUBLIN, Ireland and TREVOSE, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on ...
Read more